Miller S C, Marks S C
Division of Radiobiology, School of Medicine, University of Utah, Salt Lake City 84112.
Bone. 1993 Mar-Apr;14(2):143-51. doi: 10.1016/8756-3282(93)90241-2.
E-series prostaglandins (PGE) given systematically or locally in vivo can have powerful anabolic effects on bone. The comparative dose-response relationships from PGE1 given by osmotic minipump or controlled-release pellet on periosteal and intracortical bone envelopes were determined. Graded doses of PGE1 were delivered by osmotic minipump (0.0 to 16.7 mg PGE1/week) or controlled-release pellet (0.0 to 16.7 mg PGE1/week) to the lateral mandibular surface of adult dogs (2-5 years old). PGE1 was given for three weeks and tissues were collected for histology and histomorphometry one week later. At sites of maximal response, there were dose-related increases in the periosteal surface with new bone formation, average new bone thickness, maximum thickness, and new bone area. Subperiosteal bone formation was greater for comparable doses when PGE1 was delivered by minipumps. The proliferation of new bone at those sites treated with the pellets was greatest with the 8.3 mg PGE1/week/three week treatment. Periosteal bone formation did not appear to be preceded by a resorption phase, indicating that PGE1 treatment stimulated bone modeling in the formation mode. The new bone consisted of woven bone, particularly at sites with high accretion rates, and primary lamellar bone. There were some dose-related changes in intracortical remodeling indices including increases in cortical porosity, single and double-labeled surface, numbers of formation, reversal and resorption osteons, radial closure rate, and surface- and volume-referent bone formation rates. Increases in the bone formation rates indicate that PGE1 increased the recruitment of osteoblasts. Increases in the mineral appositional rate, observed at a higher dose, indicates that PGE1 stimulated bone production at the cellular level.(ABSTRACT TRUNCATED AT 250 WORDS)
体内系统性或局部给予E系列前列腺素(PGE)可对骨骼产生强大的合成代谢作用。测定了通过渗透微型泵或控释微丸给予PGE1对骨膜和皮质内骨膜的比较剂量-反应关系。通过渗透微型泵(0.0至16.7毫克PGE1/周)或控释微丸(0.0至16.7毫克PGE1/周)将分级剂量的PGE1给予成年犬(2至5岁)的下颌骨外侧表面。给予PGE1三周,一周后收集组织进行组织学和组织形态计量学分析。在最大反应部位,骨膜表面新骨形成、平均新骨厚度、最大厚度和新骨面积呈剂量相关增加。当通过微型泵给予PGE1时,相同剂量下骨膜下骨形成更多。用微丸治疗的部位,8.3毫克PGE1/周/三周治疗时新骨增殖最大。骨膜骨形成似乎没有吸收期,表明PGE1治疗以形成模式刺激骨塑形。新骨由编织骨组成,特别是在高沉积率部位,还有初级板层骨。皮质内重塑指标有一些剂量相关变化,包括皮质孔隙率增加、单标记和双标记表面、形成、逆转和吸收骨单位数量、径向闭合率以及表面和体积参照骨形成率增加。骨形成率增加表明PGE1增加了成骨细胞的募集。在较高剂量下观察到的矿物质沉积率增加表明PGE1在细胞水平刺激骨生成。(摘要截断于250字)